SYDNEY, Dec. 9, 2020 /PRNewswire/ -- Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA), an Australian oncology-focused biotechnology company, is pleased to share top-line final data from its phase I study of Cantrixil (TRX-E-002-1) in patients with persistent or recurrent ovarian cancer (NCT02903771).
Key Points
As Australia marks Scam Awareness Week, organisations are being urged to rethink their approach to scam prevention ...
Despite years of investment in digital engagement, from rolling out mobile apps and online portals to digital communication...
ByronBay.au, TheCairnsTimes.com.au, AirlieTimes.com.au and NoosaTimes.com have been launched as part of an expanding networ...
Cairns Regional Council has topped MobileMuster’s FY26 council collection figures in Queensland, w...
In response to Tasmania’s growing mental health crisis, a new purpose-built, multi-disciplinary me...
Since 1 July, Australian organisations have faced strengthened expectations around how they manage...
“All the world's a stage.” Shakespeare wasn't writing about Cairns when he penned that famous lin...
There was once a fairly simple bargain at the heart of social media. You joined a network. You c...
Since 1 July, Australian organisations have faced strengthened expectations around how they manage...
Every spring, I watch the same thing happen. A homeowner looks at their lawn properly for the firs...